Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Knight Therapeutics ( (TSE:GUD) ) is now available.
Knight Therapeutics reported record-high quarterly revenues for the second quarter of 2025, with a 12% increase over the previous year. Despite the revenue growth, the company faced a net loss of $12,622, attributed to hyperinflation accounting in Argentina affecting gross margins. The company entered into a revolving credit facility with National Bank of Canada and executed an asset purchase agreement with Paladin Pharma Inc., indicating strategic moves to strengthen its market position.
The most recent analyst rating on (TSE:GUD) stock is a Buy with a C$7.00 price target. To see the full list of analyst forecasts on Knight Therapeutics stock, see the TSE:GUD Stock Forecast page.
Spark’s Take on TSE:GUD Stock
According to Spark, TipRanks’ AI Analyst, TSE:GUD is a Neutral.
Knight Therapeutics’ overall stock score reflects its robust revenue growth and strategic financial moves, tempered by high valuation and profitability challenges. Technical indicators and recent corporate events support a stable outlook, but the high P/E ratio and cash flow concerns suggest caution.
To see Spark’s full report on TSE:GUD stock, click here.
More about Knight Therapeutics
Knight Therapeutics Inc. is a pan-American specialty pharmaceutical company, excluding the U.S., focused on developing and commercializing pharmaceutical products. The company aims to expand its portfolio with profitable and growth assets, including pipeline and early launch stage products.
Average Trading Volume: 61,078
Technical Sentiment Signal: Buy
Current Market Cap: C$624.8M
For a thorough assessment of GUD stock, go to TipRanks’ Stock Analysis page.